

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Telix Pharmaceuticals Limited
ABN	85 616 620 369

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Christian Behrenbruch
Date of last notice	22 May 2019

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct Interest
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	
Date of change	12 May 2020
No. of securities held prior to change	24,675,000 fully paid ordinary shares (Indirect interest - Elk River Holdings Pty Ltd as Trustee for The Behrenbruch Family Trust.) 400,000 share options with an exercise price of \$1.09 per option and an expiry date of 24 January 2023. Options vest on 24 January 2022 (Direct interest). (TLX0004)
Class	Share Options (TLX0006)

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

Number acquired	200,000 share options with an exercise price of \$2.23 per option and an expiry date of 12 January 2024. Options vest on 13 January 2023. Options granted following shareholder approval at the AGM held 12 May 2020. (TLXO006)
Number disposed	Nil
Value/Consideration <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	Options issued for nil consideration following shareholder approval at the AGM held 12 May 2020.
No. of securities held after change	24,675,000 fully paid ordinary shares (Indirect interest) 400,000 share options with an exercise price of \$1.09 per option and an expiry date of 24 January 2023. Options vest on 24 January 2022 (Direct interest). (TLXO004) 200,000 share options with an exercise price of \$2.23 per option and an expiry date of 12 January 2024. Options vest on 13 January 2023. Options granted following shareholder approval at the AGM held 12 May 2020. (TLXO006)
Nature of change <small>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</small>	Options issued following shareholder approval at the AGM held 12 May 2020.

Part 2 – Change of director's interests in contracts – NOT APPLICABLE

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	
Nature of interest	
Name of registered holder (if issued securities)	
Date of change	
No. and class of securities to which interest related prior to change <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	

+ See chapter 19 for defined terms.

For personal use only

Appendix 3Y
Change of Director's Interest Notice

Interest acquired	
Interest disposed	
Value/Consideration <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	
Interest after change	

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

+ See chapter 19 for defined terms.

For personal use only